Industry & Business

EpiCor Therapeutics wins UCD Start-up of the Year Award

 Breaking News
  • Grand Canal Innovation District Planned For Dublin A far-reaching plan for the creation of the Grand Canal Innovation District in Dublin has been launched. The proposal from Trinity College Dublin is modelled on innovation districts in cities such as Boston, Toronto, Rotterdam and Barcelona. It will significantly strengthen Ireland’s competitive advantage when developing new indigenous companies or competing for foreign direct investment. [...]...
  • Heiton Buckley Unveils Newly Refurbished Mayo Branch Heiton Buckley, Ireland’s leading supplier of doors, floors, bathrooms, garden, plumbing and heating products, has officially unveiled its newly refurbished branch in Castlebar, County Mayo . GAA star, Andy Moran, CEO of Grafton Merchanting ROI, Patrick Atkinson, Heiton Buckley Castlebar Branch Manager, Mick Kane, and longtime customer Mick Duane officially cut the ribbon and kicked [...]...
  • Export Sales by Enterprise Ireland Client Companies Hit New Record Enterprise Ireland, the state agency responsible for helping Irish companies export to international markets, has announced that its clients recorded export sales of €22.71 billion in 2017, representing a 7 per cent increase on 2016. This is the highest level of export sales recorded in the history of the agency and the eighth-consecutive year of [...]...
  • BAM Wins €25 Million Contract to Build New Cheese Factory in Cork TINE Ireland, a subsidiary of the Norwegian dairy co-operative TINE, has awarded the construction of a new Jarlsberg® cheese production facility and administration building at Mogeely, County Cork, to BAM Ireland. The contract value is more than €25 million. TINE is Norway’s largest producer, distributor and exporter of dairy products with 11,400 members (owners) and [...]...
  • HBAN Scoops Major European Business Angel Network Award HBAN (Halo Business Angel Network), the all-island organisation responsible for the promotion of business angel investment, and a joint initiative of Enterprise Ireland and InterTradeIreland, was crowned Globally Networked Organisation 2018 at the recent EBAN (European Business Angel Network) Awards Ceremony held in Sofia, Bulgaria. HBAN was awarded the prominent European accolade in recognition of the significant [...]...

EpiCor Therapeutics wins UCD Start-up of the Year Award

EpiCor Therapeutics wins UCD Start-up of the Year Award
November 23
13:18 2016

Biotech start-up EpiCor Therapeutics won the UCD Start-Up of the Year Award 2016 on Thursday, November 17. It received a €20,000 prize as part of the overall winner award of the UCD VentureLaunch Accelerator Programme. The start-up is aiming to develop a treatment for hypertrophic obstructive cardiomyopathy (HOCM), a significant cause of sudden cardiac death.

HOCM is a disease in which a portion of the heart muscle is enlarged without any obvious cause resulting in impairment of the heart. Symptoms include shortness of breath, chest pain and heart palpitations. In the US alone, HOCM currently affects around 175,000 people with associated annual healthcare costs amounting to over $1 billion.

EpiCor Therapeutics is currently focused on repurposing an existing drug, 5-azacytidine, for the treatment of HOCM. It will also investigate the use of biomarkers to deliver targeted treatment for individuals.

EpiCor Therapeutics was founded by Dr John Baugh, Dr Nadia Glezeva, Dr Chris Watson, Dr Mark Ledwidge and Professor Ken McDonald, all of UCD School of Medicine.

“It is an honour for EpiCor Therapeutics to win the 2016 UCD Start-up of the Year Award,” said Dr John Baugh. “It is a great endorsement for us going forward as we work to develop treatments to target a variety of heart diseases, including our initial focus on hypertrophic obstructive cardiomyopathy.

The disease has no approved disease-modifying therapeutics, is a significant cause of sudden cardiac death of individuals in any age group and a leading cause of such death in young athletes.

EpiCor Therapeutics is now seeking to raise €750,000 in seed funding to enable pre-clinical bridging studies. Following additional fund raising, it plans to proceed with a clinical proof-of-concept study to support its approval as a treatment for HOCM.

UCD’s annual VentureLaunch Accelerator Programme aims to support and accelerate the launch of sustainable and profitable new ventures based on intellectual property emerging from the university.

About Author

editor

editor

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4